株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

CountryFocus:英国の医療・規制・医療費償還制度の情勢

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - UK

発行 GlobalData 商品コード 284115
出版日 ページ情報 英文 253 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: GlobalData社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
CountryFocus:英国の医療・規制・医療費償還制度の情勢 CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - UK
出版日: 2016年03月01日 ページ情報: 英文 253 Pages
概要

当レポートでは、英国の医療・規制・医療費償還制度について調査分析し、医薬品・医療機器市場の概要、医療費償還制度とその関連情報、規制当局の構造や規制の概要、国の情勢、医療インフラなどの最新情報を提供しています。

第1章 目次

第2章 イントロダクション

第3章 医薬品・医療機器市場の概要

  • 医薬品市場
  • 医療機器市場
  • 市場促進要因・障壁

第4章 市場参入

  • 医療費償還・保険料払込者の情勢
  • 規制情勢

第5章 国の分析

  • 政策環境
  • 経済情勢
  • 経済指標
  • 人口統計
  • 医療インフラ
  • 医療費
  • 産業団体
  • 見本市

第6章 機会と課題

  • 機会
  • 課題

第7章 付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHC0053CHR

GlobalData, the industry analysis specialist, has released its new report, "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - UK". The report is an essential source of information and an analysis on the healthcare, regulatory and reimbursement landscape of the UK. The report identifies the key trends in the healthcare market and provides insights on the demographic, regulatory, reimbursement landscape and healthcare infrastructure of the UK. Most importantly, the report provides valuable insights on the trends and segmentation of the pharmaceutical and medical devices market. This report is built using data and information sourced from proprietary databases, secondary research and in-house analysis by GlobalData's team of industry experts.

In 2014, the UK`s population was approximately 64.2 million. The major factors contributing to the growth in the population are increase in net migration and decrease in death rate. The UK policymakers are now presented with the problems of a Eurozone crisis, a declining population of the working age group and an increasing elderly population. The pharmaceutical market in the UK was estimated at $28.8 billion in 2015 and is expected to reach approximately $43.2 billion by 2020 with a projected Compound Annual Growth Rate (CAGR) of 8.4%. The medical devices market size was approximately $14.4 billion in 2015 and is expected to reach approximately $17.9 billion by 2020 with a projected CAGR of 4.5%.

The positive trends in the UK healthcare market can be attributed primarily to -

  • Increasing elderly population
  • Universal healthcare insurance
  • High degree of access to healthcare facilities

Scope

The report provides information on the healthcare, regulatory and reimbursement landscape of the UK. The scope includes -

  • Overview of the pharmaceutical and medical devices market of the UK including the market size, market segmentation, key drivers and barriers.
  • Profile and SWOT analysis of the major players in the pharmaceutical and medical devices market. The key players covered for the pharmaceutical market are Pfizer, GlaxoSmithKline, Novartis, Roche and Merck. The key players covered for the medical devices market are Essilor International, GlaxoSmithKline, DePuy Companies, Johnson & Johnson and B.Braun.
  • Insightful review on the reimbursement and regulatory landscape. Analysis includes details of the healthcare reimbursement process, the regulatory agencies and the approval processes for new drugs and medical devices.
  • A detailed analysis of the political and economic environment of the UK including the economic indicators, demographics, healthcare infrastructure and healthcare expenditure.
  • An overview of the opportunities and challenges for growth that exist in the healthcare market of the UK.

Reasons to buy

The report on the UK comprehensively covers both the pharmaceutical and the medical devices markets of the UK. The report will enhance your decision making capability. It will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the healthcare market of the UK.
  • Drive revenue by understanding the key trends, and reimbursement and regulatory policies, pharmaceutical and medical devices market segments and companies likely to impact the the UK healthcare market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of the various competitors.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present the maximum opportunities for consolidations, investments and strategic partnerships.
  • Identify, understand and capitalize on the opportunities and challenges in the healthcare market of the UK.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. GlobalData Report Guidance

3. Overview of the Pharmaceutical and Medical Device Markets

  • 3.1. Pharmaceutical Market
    • 3.1.1. Market Overview
    • 3.1.2. Pharmaceutical Exports and Imports
    • 3.1.3. Supply Channels
    • 3.1.4. Market Segments
    • 3.1.5. Major Therapeutic Areas
    • 3.1.6. Major Companies
  • 3.2. Medical Device Market
    • 3.2.1. Market Overview
    • 3.2.2. Overview of Top Five Segments
    • 3.2.3. Diagnostic market
    • 3.2.4. Major Players
  • 3.3. Market Drivers and Barriers
    • 3.3.1. Drivers
    • 3.3.2. Barriers

4. Market Access

  • 4.1. Reimbursement and Payer Landscape
    • 4.1.1. Overview of Healthcare System
    • 4.1.2. Reimbursement Process
    • 4.1.3. Overview of Insurance Providers
    • 4.1.4. Patient Share in Healthcare Spending
    • 4.1.5. Drug Price Change
    • 4.1.6. Pricing Policies
  • 4.2. Regulatory Landscape
    • 4.2.1. Overview of Regulatory Agencies
    • 4.2.2. Market Authorization Procedure for Pharmaceutical Products
    • 4.2.3. New Medical Device Approval Process
    • 4.2.4. Licensing Process for Pharmaceutical Manufacturing
    • 4.2.5. Intellectual Property Rights
    • 4.2.6. Clinical Trial Regulations
    • 4.2.7. Pharmaceutical Advertising Regulations
    • 4.2.8. Pharmacy Regulations
    • 4.2.9. Labeling and Packaging Regulations

5. Country Analysis

  • 5.1. Political Environment
    • 5.1.1. Political Structure
    • 5.1.2. Analysis of the Current Political Environment
    • 5.1.3. Healthcare Policy Initiatives
  • 5.2. Economic Landscape
  • 5.3. Economic Indicators
    • 5.3.1. Gross Domestic Product
    • 5.3.2. Gross National Income
    • 5.3.3. Inflation
    • 5.3.4. Currency Exchange Rate
    • 5.3.5. Foreign Direct Investment
    • 5.3.6. Foreign Exchange Reserves
    • 5.3.7. Trade Balance
    • 5.3.8. Government Structural Balance
    • 5.3.9. General Government Gross Debt
    • 5.3.10. External Debt
    • 5.3.11. Major Industries
  • 5.4. Demographics
    • 5.4.1. Population
    • 5.4.2. Education and Literacy
    • 5.4.3. Employment
    • 5.4.4. Disease Burden
  • 5.5. Healthcare Infrastructure
    • 5.5.1. Healthcare Facilities
    • 5.5.2. Healthcare Parameters
    • 5.5.3. Environmental Health
    • 5.5.4. Healthcare Personnel
  • 5.6. Healthcare Expenditure
    • 5.6.1. Overview
    • 5.6.2. Components of Healthcare Spending
    • 5.6.3. Public and Private Sector Share
    • 5.6.4. Spending in Pharmaceutical R&D
  • 5.7. Trade Associations
    • 5.7.1. Association of the British Pharmaceutical Industry (ABPI)
    • 5.7.2. British In Vitro Diagnostics Association (BIVDA)
    • 5.7.3. National Pharmacy Association (NPA)
    • 5.7.4. Association of British Healthcare Industries (ABHI)
    • 5.7.5. British Generic Manufacturers Association (BGMA)
  • 5.8. Trade Fairs

6. Opportunities and Challenges

  • 6.1. Opportunities
  • 6.2. Challenges

7. Appendix

  • 7.1. Abbreviations
  • 7.2. Bibliography
  • 7.3. Research Methodology
    • 7.3.1. Coverage
    • 7.3.2. Secondary Research
    • 7.3.3. Forecasts
    • 7.3.4. Expert Panel
  • 7.4. Disclaimer

List of Tables

  • Table 1: Pharmaceutical Market, UK, Revenue ($bn), 2008-2015
  • Table 2: Pharmaceutical Market, UK, Revenue ($bn), 2016-2020
  • Table 3: Pharmaceutical Market, UK, Revenue by Exports and Imports ($bn), 2008-2015
  • Table 4: Major Therapeutic Areas, UK, Prescribing cost ($bn) , 2015
  • Table 5: Pharmaceutical Market, UK, NHS Gross Expenditure on Neurological Issues ($bn), 2008-2015
  • Table 6: Pharmaceutical Market, UK, NHS Gross Expenditure on Endocrine System Issues ($bn), 2008-2015
  • Table 7: Pharmaceutical Market, UK, NHS Gross Expenditure on Respiratory System Problems ($bn), 2008-2015
  • Table 8: Pharmaceutical Market, UK, NHS Gross Expenditure on Cardiovascular System Problems ($bn), 2008-2015
  • Table 9: Pharmaceutical Market, UK, NHS Gross Expenditure on Nutrition and Blood Problems ($bn), 2008-2015
  • Table 10: Pharmaceutical Market, Pfizer, Global, Major Products by Revenue ($bn) and Annual Growth (%), Revenue, 2014
  • Table 11: Pharmaceutical Market, Pfizer, Global, Late-Stage Pipeline, 2015
  • Table 12: Pharmaceutical Market, GlaxoSmithKline, Global, Major Products, Revenue ($bn) and Annual Growth (%), 2014
  • Table 13: Pharmaceutical Market, GlaxoSmithKline, Global, Late-Stage Pipeline, 2015
  • Table 14: Pharmaceutical Market, Novartis, Global, Major Products, Revenue ($bn) and Annual Growth (%), 2013
  • Table 15: Pharmaceutical Market, Novartis, Global, Planned Filings, 2016-2019
  • Table 16: Pharmaceutical Market, Roche, Global, Major Products, Revenue ($m) and Annual Growth (%), 2013
  • Table 17: Pharmaceutical Market, Roche, Global, Late-stage Pipeline, 2013
  • Table 18: Pharmaceutical Market, Merck, Global, Major Products, Revenue ($bn) and Annual Growth (%), 2013
  • Table 19: Pharmaceutical Market, Merck, Global, Late-Stage Pipeline, 2014
  • Table 20: Medical Device Market, UK, Revenue ($bn), 2008-2015
  • Table 21: Medical Device Market, UK, Revenue ($bn), 2016-2020
  • Table 22: Medical Device Market, UK, Revenue ($bn), 2014
  • Table 23: Medical Device Market, UK, Orthopedic Devices Market, Revenue ($bn), 2008-2015
  • Table 24: Medical Device Market, UK, Orthopedic Devices Market, Market Share (%), 2014
  • Table 25: Medical Device Market, UK, Ophthalmic Devices, Market Revenue ($bn), 2008-2015
  • Table 26: Medical Device Market, UK, Ophthalmic Devices, Market Share (%), 2014
  • Table 27: Medical Device Market, UK, Wound Care Management Market, Revenue ($bn), 2008-2015
  • Table 28: Medical Device Market, UK, Wound Care Management, Market Share (%), 2012
  • Table 29: Medical Device Market, UK, Cardiovascular Device Market, Revenue ($bn), 2008-2015
  • Table 30: Medical Device Market, UK, Cardiovascular Device Market, Market Share, 2012
  • Table 31: Medical Device Market, UK, In-vitro Diagnostic Devices Market, Revenue ($bn), 2008-2015
  • Table 32: Medical Device Market, UK, In-vitro Diagnostic Devices Market, Share (%), 2012
  • Table 33: Medical Device Market, UK, Diagnostic Market, Revenue ($bn), 2008-2015
  • Table 34: Medical Device Market, UK, Diagnostic Market, Revenue ($bn), 2016-2020
  • Table 35: Medical Device Market, GlaxoSmithKline, Global, Major Products, Revenue ($bn) and Annual Growth (%), 2014
  • Table 36: Healthcare Spending, UK, Out-of-pocket Expenditure (% of Private Expenditure on Health), 2008-2015
  • Table 37: Market Access, UK, Drug Price Change (%), 2008-2015
  • Table 38: Market Access, UK, Schedule of Patent Fees, 2015
  • Table 39: Market Access, UK, Schedule of Trademark Fees, 2015
  • Table 40: Market Access, UK, Clinical Trials Application Fees, 2015
  • Table 41: Market Access, UK, Clinical trials application fees, 2015
  • Table 42: Economic Indicators, UK, GDP per Capita ($), 2008-2015
  • Table 43: Economic Indicators, UK, GDP per Capita ($), 2016-2020
  • Table 44: Economic Indicators, UK, GDP Annual Growth (%), 2008-2015
  • Table 45: Economic Indicators, UK, GDP Annual Growth (%), 2016-2020
  • Table 46: Economic Indicators, UK, National Income ($ tn), 2008-2014
  • Table 47: Economic Indicators, UK, Average Consumer Price Index, 2008-2015
  • Table 48: Economic Indicators, UK Average Consumer Price Index, 2016-2020
  • Table 49: Economic Indicators, UK, Average Consumer Price Annual Change (%), 2008-2014
  • Table 50: Economic Indicators, UK, Currency Exchange Rate (£ to $), 2008-2014
  • Table 51: Economic Indicators, UK, FDI ($bn), 2008-2014
  • Table 52: Economic Indicators, UK, Foreign Exchange Reserves ($bn), 2008-2014
  • Table 53: Economic Indicators, UK, Imports of Goods and Services ($bn), 2008-2014
  • Table 54: Economic Indicators, UK, Exports of Goods and Services ($bn), 2008-2014
  • Table 55: Economic Indicators, UK, Government Structural Balance ($bn), 2008-2014
  • Table 56: Economic Indicators, UK, General Government Gross Debt (% of GDP), 2008-2015
  • Table 57: Economic Indicators, UK, General Government Gross Debt (% of GDP), 2016-2020
  • Table 58: Economic Indicators, UK, External Debt ($tr), 2008-2014
  • Table 59: Economic Indicators, UK, Major Industries, National Income by Industry ($bn), 2013
  • Table 60: Demographics, UK, Population (million), 2008-2014
  • Table 61: Demographics, UK, Population Forecast (million), 2016-2020
  • Table 62: Demographics, UK, Urban and Rural Population (%), 2008-2014
  • Table 63: Demographics, UK, Population Distribution by Age Group (%), 2008-2015
  • Table 64: Demographics, UK, Population Distribution by Age Group (%), 2016-2020
  • Table 65: Demographics, UK, Births (per 1,000 Population), 2008-2014
  • Table 66: Demographics, UK, Mortality (per 1,000 Population), 2008-2014
  • Table 67: Demographics, UK, Major Causes of Mortality (%), 2014
  • Table 68: Demographics, UK, Infant Mortality (per 1,000 Live Births), 2008-2014
  • Table 69: Demographics, UK, Immunization Rate (%), 2013
  • Table 70: Demographics, UK, Major Causes of Male Mortality ('000), 2014
  • Table 71: Demographics, UK, Major Causes of Female Mortality ('000), 2014
  • Table 72: Demographics, UK, Gender Ratio (M/F), 2008-2014
  • Table 73: Demographics, UK, Life Expectancy at Birth (Years), 2008-2014
  • Table 74: Demographics, UK, Gross Enrollment (%), 2008-2015
  • Table 75: Demographics, UK, Unemployment Rate (%), 2008-2014
  • Table 76: Demographics, UK, Disease Burden, DALYs (per 100,000 population), 2013
  • Table 77: Healthcare Infrastructure, UK, Beds by Type of Service, 2008-2014
  • Table 78: Healthcare Infrastructure, UK, Diagnostic Equipment (Per Million Population), 2008-2014
  • Table 79: Healthcare Infrastructure, UK, Hospital Beds (per 1,000 Population), 2008-2014
  • Table 80: Healthcare Infrastructure, UK, Doctors (per 1,000 population), 2008-2014
  • Table 81: Healthcare Infrastructure, UK, CO2 emissions (million), 2008-2014
  • Table 82: Healthcare Infrastructure, UK, CH4 emissions (million tons), 2008-2014
  • Table 83: Healthcare Infrastructure, UK, PM10 (µg/m3), 2008-2014
  • Table 84: Healthcare Infrastructure, UK, Nurses (Per 1,000 Population), 2008-2014
  • Table 85: Healthcare Infrastructure, UK, Pharmacists (per 1,000 Population), 2008-2014
  • Table 86: Healthcare Infrastructure, UK, Dentists (Per 1,000 Population), 2008-2014
  • Table 87: Healthcare Expenditure, UK, Healthcare Expenditure (% of GDP), 2008-2014
  • Table 88: Healthcare Expenditure , UK, Consumption Expenditure on Medical Goods and Services, Share (%), 2013
  • Table 89: Healthcare Expenditure, UK, Public and Private Share of Healthcare Expenditure (%), 2008-2014
  • Table 90: Healthcare Expenditure, UK, Pharmaceutical R&D Expenditure ($bn), 2008-2014
  • Table 91: Major Healthcare Trade Fairs, UK, 2016

List of Figures

  • Figure 1: Pharmaceutical Market, UK, Revenue ($bn), 2008-2015
  • Figure 2: Pharmaceutical Market, UK, Revenue ($bn), 2016-2020
  • Figure 3: Pharmaceutical Market, UK, Revenue by Exports and Imports ($bn), 2008-2015
  • Figure 4: Pharmaceutical Market, UK, Supply Channels, 2014
  • Figure 5: Pharmaceutical Market, UK, Generic Launch, 2013
  • Figure 6: Major Therapeutic Areas, UK, Prescribing Cost ($bn), 2015
  • Figure 7: Pharmaceutical Market, UK, NHS Gross Expenditure on Neurological Issues ($bn), 2008-2015
  • Figure 8: Pharmaceutical Market, UK, NHS Gross Expenditure on Endocrine System Issues ($bn), 2008-2015
  • Figure 9: Pharmaceutical Market, UK, NHS Gross Expenditure on Respiratory System Issues ($bn), 2008-2015
  • Figure 10: Pharmaceutical Market, UK, NHS Gross Expenditure on Cardiovascular System Issues ($bn), 2008-2015
  • Figure 11: Pharmaceutical Market, UK, NHS Gross Expenditure on Nutrition and Blood Issues ($bn), 2008-2015
  • Figure 12: Medical Device Market, UK, Revenue ($bn), 2008-2015
  • Figure 13: Medical Device Market, UK, Revenue ($bn), 2016-2020
  • Figure 14: Medical Device Market, UK, Revenue ($bn), 2014
  • Figure 15: Medical Device Market, UK, Orthopedic Devices Market, Revenue ($bn), 2008-2015
  • Figure 16: Medical Device Market, UK, Orthopedic Devices Market, Market Share (%), 2014
  • Figure 17: Medical Device Market, UK, Ophthalmic Devices, Market Revenue ($bn), 2008-2015
  • Figure 18: Medical Device Market, UK, Ophthalmic Devices Market Share (%), 2012
  • Figure 19: Medical Device Market, UK, Wound Care Management Market, Revenue ($bn), 2008-2015
  • Figure 20: Medical Device Market, UK, Wound Care Management, Market Share (%), 2012
  • Figure 21: Medical Device Market, UK, Cardiovascular Device Market, Revenue ($bn), 2008-2015
  • Figure 22: Medical Device Market, UK, Cardiovascular Device Market, Share (%), 2012
  • Figure 23: Medical Device Market, UK, In-vitro Diagnostic Devices Market, Revenue ($bn), 2008-2015
  • Figure 24: Medical Device Market, UK, In-vitro Diagnostic Devices Market, Share (%), 2012
  • Figure 25: Medical Device Market, UK, Diagnostic Market, Revenue ($bn), 2008-2015
  • Figure 26: Medical Device Market, UK, Diagnostic Market, Revenue ($bn), 2016-2020
  • Figure 27: Healthcare Market, UK, Drivers and Barriers, 2015
  • Figure 28: Healthcare System, UK, 2015
  • Figure 29: Healthcare Spending, UK, Out-of-pocket Expenditure (% of Private Expenditure on Health), 2008-2015
  • Figure 30: Market Access, UK, Drug Price Change (%), 2008-2015
  • Figure 31 Healthcare System, UK, MHRA Structure, 2015
  • Figure 32: Healthcare System, UK, National Procedure for Market Authorization, 2015
  • Figure 33: Healthcare System, EU, Centralized Procedure, Pre-Submission, 2015
  • Figure 34: Healthcare System, EU, Centralized Procedure, Marketing Authorization, Pre-Opinion Phase, 2015
  • Figure 35: Healthcare System, EU, Centralized Procedure, Marketing Authorization, Post-opinion Phase, 2015
  • Figure 36: Healthcare System, EU, Decentralized Procedure, 2015
  • Figure 37: Healthcare System, EU, Mutual Recognition Procedure, 2015
  • Figure 38: Healthcare System, EU, Conformity Assessment of Class I Medical Devices, 2013
  • Figure 39: Healthcare System, EU, Conformity Assessment of Class IIa Medical Devices, 2013
  • Figure 40: Healthcare System, EU, Conformity Assessment of Class IIb Medical Devices, 2013
  • Figure 41: Healthcare System, EU, Conformity Assessment of Class III Medical Devices, 2013
  • Figure 42: Healthcare System, UK, Patent Approval Process, 2015
  • Figure 43: Healthcare System, UK, Clinical Trial Regulation Process for Medicines, 2015
  • Figure 44: Healthcare System, UK, Clinical Trial Regulation Process for Medical Devices, 2013
  • Figure 45: Economic Indicators, UK, GDP per Capita ($), 2008-2015
  • Figure 46: Economic Indicators, UK, GDP per Capita ($), 2016-2020
  • Figure 47: Economic Indicators, UK, GDP Annual Growth (%), 2008-2015
  • Figure 48: Economic Indicators, UK, GDP Annual Growth (%), 2016-2020
  • Figure 49: Economic Indicators, UK, National Income ($tn), 2008-2014
  • Figure 50: Economic Indicators, UK, Average Consumer Price Index, 2008-2015
  • Figure 51: Economic Indicators, UK, Average Consumer Price Index, 2016-2020
  • Figure 52: Economic Indicators, UK, Average Consumer Price Annual Change (%), 2008-2014
  • Figure 53: Economic Indicators, UK, Currency Exchange Rate ($ to £), 2008-2014
  • Figure 54: Economic Indicators, UK, FDI ($bn), 2008-2014
  • Figure 55: Economic Indicators, UK, Foreign Exchange Reserves ($bn), 2008-2014
  • Figure 56: Economic Indicators, UK, Imports of Goods and Services ($bn), 2008-2014
  • Figure 57: Economic Indicators, UK, Exports of Goods and Services ($bn), 2008-2014
  • Figure 58: Economic Indicators, UK, Government Structural Balance ($bn), 2008-2014
  • Figure 59: Economic Indicators, UK, General Government Gross Debt (% of GDP), 2008-2015
  • Figure 60: Economic Indicators, UK, General Government Gross Debt (% of GDP), 2016-2020
  • Figure 61: Economic Indicators, UK, External Debt ($tn), 2008-2014
  • Figure 62: Economic Indicators, UK, Major Industries, Gross Value Added ($bn), 2013
  • Figure 63: Demographics, UK, Population (million), 2008-2015
  • Figure 64: Demographics, UK, Population (million), 2016-2020
  • Figure 65: Demographics, UK, Urban and Rural Population (%), 2008-2014
  • Figure 66: Demographics, UK, Population Distribution by Age Group (%), 2008-2015
  • Figure 67: Demographics, UK, Population Distribution by Age Group (%), 2016-2020
  • Figure 68: Demographics, UK, Births (per 1,000 Population), 2008-2014
  • Figure 69: Demographics, UK, Mortality (per 1,000 Population), 2008-2014
  • Figure 70: Demographics, UK, Major Causes of Mortality (%), 2014
  • Figure 71: Demographics, UK, Infant Mortality (per 1,000 Live Births), 2008-2014
  • Figure 72: Demographics, UK, Immunization Rate (%), 2013
  • Figure 73: Demographics, UK, Major Causes of Male Mortality ('000), 2014
  • Figure 74: Demographics, UK, Major Causes of Female Mortality ('000), 2014
  • Figure 75: Demographics, UK, Gender Ratio (M/F), 2008-2014
  • Figure 76: Demographics, UK, Life Expectancy at Birth (Years), 2008-2014
  • Figure 77: Demographics, UK, Gross Enrollment (%), 2008-2015
  • Figure 78: Demographics, UK, Unemployment Rate (%), 2008-2014
  • Figure 79: Demographics, UK Disease Burden, DALYs (per 100,000 population), 2013
  • Figure 80: Healthcare Infrastructure, UK, Beds by Type of Service, 2008-2014
  • Figure 81: Healthcare Infrastructure, UK, Diagnostic Equipment (Per Million Population), 2008-2014
  • Figure 82: Healthcare Infrastructure, UK, Hospital Beds (Per 1,000 Population), 2008-2014
  • Figure 83: Healthcare Infrastructure, UK, Doctors (per 1,000 population), 2008-2014
  • Figure 84: Healthcare Infrastructure, UK, CO2 emissions (million tons), 2008-2014
  • Figure 85: Healthcare Infrastructure, UK, CH4 emissions (million tons)2008-2014
  • Figure 86: Healthcare Infrastructure, UK, PM10 (µg/m3), 2008-2014
  • Figure 87: Healthcare Infrastructure, UK, Nurses (Per 1,000 Population), 2008-2014
  • Figure 88: Healthcare Infrastructure, UK, Pharmacists (per 1,000 Population), 2008-2014
  • Figure 89: Healthcare Infrastructure, UK, Dentists (Per 1,000 Population), 2008-2014
  • Figure 90: Healthcare Expenditure, UK, Healthcare Expenditure (% of GDP), 2008-2014
  • Figure 91: Healthcare Expenditure , UK, Consumption Expenditure on Medical Goods and Services, Share (%), 2013
  • Figure 92: Healthcare Expenditure, UK, Public and Private Share of Healthcare Expenditure (%), 2008-2014
  • Figure 93: Healthcare Expenditure, UK, Pharmaceutical R&D Expenditure ($bn), 2008-2014
  • Figure 94: Healthcare Market, UK, Opportunities and Challenges, 2015
Back to Top